{
    "nct_id": "NCT00076440",
    "title": "Antigonadotropin-Leuprolide in Alzheimer's Disease Drug INvestigation (ALADDIN) VP 104 Study",
    "status": "COMPLETED",
    "last_update_time": "2009-12-10",
    "description_brief": "ALADDIN is a research study to investigate the safety and effectiveness of leuprolide (a hormone drug) to improve the cognitive function and slow the progression of Alzheimer's disease (AD) in men 65 years and older with mild to moderate Alzheimer's disease who reside in the community.",
    "description_detailed": "ALADDIN is a clinical trial investigating the safety and effectiveness of leuprolide (a hormone drug) to improve the cognitive function and slow the progression of Alzheimer's disease (AD). The study will include treatment of men 65 years and older with mild to moderate Alzheimer's disease who reside in the community. The objective is to evaluate the safety and efficacy of two different doses of leuprolide to improve the cognitive function and slow the progression of AD, as measured by the ADAS-COG and the Clinical Global Impression (CGI). Measures of behavioral disturbances, and quality of life of the caregiver will be made also. The study design is randomized, double blind, placebo-controlled, parallel group design with a 2:1 randomization of drug to placebo. Sample size will include 90 participants from multiple test sites.\n\nFollowing initial screening and baseline visits, the participant and caregiver will visit the site 8 times for a total of 10 visits over 48 weeks. The drug is administered via injection every 3 months. Safety assessments are completed and psychometric testing is done. Participant's memory, behavior, and global functioning are assessed during the participant and caregiver interviews. Each visit takes approximately 2 hours.",
    "phase": [
        "PHASE2"
    ],
    "study_type": "INTERVENTIONAL",
    "primary_purpose": "TREATMENT",
    "results": null,
    "target_category": "disease-targeted biologic",
    "drug": [
        "leuprolide (leuprolide acetate; e.g., Lupron; VP4896)"
    ],
    "placebo": [
        "placebo (injection)"
    ],
    "explanation_target": [
        "Reason: The trial tests leuprolide, a gonadotropin-releasing-hormone (GnRH) analogue/peptide (leuprolide acetate) given by injection to lower luteinizing hormone (LH) with the stated intent to improve cognition and slow Alzheimer's progression \u2014 i.e., an intervention intended to modify disease biology rather than only treat symptoms, so it fits the 'disease-targeted' definition. \ue200cite\ue202turn0search2\ue202turn0search8\ue201",
        "Act: Key details from web sources \u2014 ALADDIN (VP 104 / NCT00076440) evaluated leuprolide for safety and efficacy in men with mild\u2013moderate AD. Leuprolide/VP4896 is described as a GnRH agonist that decreases pituitary LH release; the hypothesis is that lowering LH/gonadotropins may affect AD pathology (amyloid-related mechanisms) and stabilize cognition. (See ALADDIN/VP-AD descriptions and background on leuprolide trials and rationale.) \ue200cite\ue202turn0search6\ue202turn0search8\ue202turn0search5\ue201",
        "Reflect: Classification check \u2014 leuprolide is a synthetic peptide hormone analogue (not a small molecule) repurposed to target a proposed pathogenic pathway (gonadotropin/LH signaling) in AD; therefore the best matching category is 'disease-targeted biologic'. I note some ambiguity because leuprolide is not an antibody/vaccine but is a peptide biologic; given the provided category definitions (biologics vs small molecules), peptide GnRH analogues are most appropriately placed under 'disease-targeted biologic'. Additional supporting/related trials and protocols (e.g., LUCINDA, Lupron depot Phase II reports) are available for reference. \ue200cite\ue202turn0search1\ue202turn0search0\ue201"
    ],
    "agent_type": "L) Growth Factors and Hormones",
    "explanation_agent": [
        "Reason: The investigational drug is leuprolide (leuprolide acetate), a gonadotropin\u2011releasing hormone (GnRH) analogue that\u2014with continuous administration\u2014downregulates pituitary gonadotropin (LH/FSH) release and thereby alters sex\u2011hormone signaling; the trial rationale is to modify gonadotropin/LH\u2011related hormonal pathways thought to influence AD biology. \ue200cite\ue202turn0search0\ue202turn0search3\ue201",
        "Act: Key extracted details \u2014 drug: leuprolide (VP4896 / Lupron), mechanism: GnRH agonist that ultimately decreases LH/FSH (antigonadotropic effect), trial: ALADDIN (Antigonadotropin\u2011Leuprolide in Alzheimer's Disease, NCT00076440 / VP\u2011104) testing leuprolide in men with mild\u2013moderate AD. These facts support classification under a hormone\u2011based CADRO category. \ue200cite\ue202turn1search0\ue202turn0search6\ue202turn0search0\ue201",
        "Reflect: Mapping to CADRO \u2014 leuprolide targets a hormonal/growth\u2011factor signaling axis (hypothalamic\u2011pituitary\u2011gonadal/gonadotropin pathway), not amyloid, tau, innate immunity, synaptic receptors, or proteostasis directly. The closest and most specific CADRO category is L) Growth Factors and Hormones. There is no strong evidence in the trial description that multiple disparate CADRO categories are being targeted, so 'R) Multi\u2011target' is not appropriate. (If future data showed the drug primarily acted via amyloid\u2011specific mechanisms, reclassification could be considered, but current rationale is hormonal.)",
        "Web search results (selected):",
        "- Trial record for ALADDIN (NCT00076440) \u2014 study details and interventions. \ue200cite\ue202turn1search0\ue201",
        "- MedPath / trial summary for ALADDIN (VP\u2011104) describing leuprolide use in AD. \ue200cite\ue202turn0search1\ue201",
        "- Mechanism summary for leuprolide (GnRH agonist \u2192 downregulates LH/FSH with continuous dosing). \ue200cite\ue202turn0search0\ue202turn0search3\ue201",
        "- VP4896 / later development summaries (study listings/descriptions). \ue200cite\ue202turn0search6\ue201"
    ]
}